{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2519204"],"location":["Greece","Austria","Belgium","Italy","France","Germany"],"study_start_month":["11"],"keyword":["UFT","5-FU"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A randomized, open-label phase II studyevaluating the efficacy and safety of FOLFOX-4plus cetuximab versus UFOX plus cetuximab asfirst-line therapy in subjects with metastaticcolorectal cancer","description":"Primary objectives: The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer.\nPrimary endpoints: The primary variable is progression-free survival.","dates":{"creation":"2006-11-15"},"accession":"2519204","cross_references":{"EU Clinical Trials Register":["2006-000685-36"]}}